Hormone therapy for prostate cancer has come a long way in the past few decades. Not so long ago, the only hormonal treatment for this disease was drastic: an orchiectomy, the surgical removal of ...

Hormone therapy can make a big difference for men with recurrent or metastatic prostate cancer. But it isn't a cure. Its effects are limited and the side effects can be difficult to cope with.

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

Androgens are hormones that control the development of male sexual characteristics. The most powerful of the androgens is called ...

Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor ...

It has seen patients take abiraterone, which stops the body producing the hormone testosterone, in combination with standard treatment for locally advanced prostate cancer. Prostate cancer ...

The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of osteoporosis in men. Observations are consistent with this effect ...

790 patients with treatment-na-ve hormone-sensitive metastatic prostate cancer were randomized to either ADT plus docetaxel or ADT alone. [7] The primary end point of this study was OS.

A clinical trial for prostate cancer testing the BCL2 inhibitor venetoclax—a drug approved for types of leukemia—with the ...

independent of the traditional methods for prostate cancer elimination that include hormone therapy, chemotherapy, and various methods of radiation therapy. "Because the CAR-T program uses a novel ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

ADT, androgen-deprivation therapy; DOC, docetaxel; FDA, US Food and Drug Administration; mHSPC, metastatic hormone-sensitive prostate cancer; RCT, randomized controlled trial. We considered the ...